• About Us
    • Why Choose IntegraLabs?
    • Accreditation / Licensures
    • Billing Policy
    • Mission Statement
    • Overview
  • Product Services
    • SARS-COV-2, COVID-19 TESTING
    • COVID-19 Testing
    • Oral Fluids
    • Urine Toxicology
    • Women’s Health Testing
    • UTI Testing
    • Genetic Testing
  • Resources
    • Articles / News / Updates
    • Fee Schedule
    • Drug Reference / Detection Time Sheet
    • HIPAA
  • Contact Us
    • Testing Supply Order Form
    • Client Satisfaction Survey
  • Schedule a Pickup
  • Portal LogIn

Articles / News / Updates

HomeArticles / News / Updates

News in Pain Medicine

 

FDA Warns of Slowed-Breathing Risks Associated With Tramadol Use in Children

 

HHS Announces Loosening of Buprenorphine Patient Limit

 

Focus on Reducing Opioid Abuse, Misuse May Harm True Chronic Pain Patients

 

FDA Approves Oxycontin use for ages 11 – 16

 

Why America Can’t Kick Its Painkiller Problem

 

Controlled Substance Monitoring & Drugs Of Abuse Coding & Billing Guidelines (M00109, V6) – Effective April 1, 2015C

 

New 2015 CMS G Codes Update

 

New CMS LCD effective Jan. 1, 2015 (L35105 Controlled Substance Monitoring and Drugs of Abuse Testing Palmetto)

 

Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature: Journal of the American Academy of Child and Adolescent Psychiatry

 

Urine Drug Testing and Monitoring in Pain Management :
Scientifically sound urine drug testing of pain patients can be an effective means to augment pharmacotherapy and assist with complex medical/legal aspects of the current healthcare environment.

 

Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II

 

DEA placement of Tramadol into schedule IV

 

© 2021 Integra Labs. All rights reserved.